| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Not applicable (polymer vehicle/excipient). PEG-bis-amine is a biocompatible polymer that does not have a specific therapeutic target; rather, it is used as a drug delivery carrier, hydrogel scaffold, or surface modifier.
|
|---|---|
| ln Vitro |
PEG-bis-amine is not a drug and has no inherent enzyme inhibitory or cell-killing activity. Its "activity" is physicochemical: the terminal amine groups can covalently attach to biomolecules (e.g., proteins, drugs, targeting ligands) via amide bond formation. It enhances solubility, reduces immunogenicity, and prolongs circulation time of conjugated therapeutics.
|
| ln Vivo |
PEG-bis-amine has been used in vivo to synthesize folate-conjugated polymer micelles for encapsulating anticancer agents such as 9-nitrocamptothecin. Micelles formed with PEG-bis-amine can target tumors via folate receptor-mediated endocytosis. The polymer itself is inert and biocompatible, making it a safe and effective drug delivery vehicle in animal models.
|
| Enzyme Assay |
Cell-free assays for PEG-bis-amine are not typical. However, for bioconjugation: the polymer is dissolved in an appropriate buffer (e.g., MES or PBS, pH 5-7.5). A crosslinker such as EDC/NHS is added to activate the amine groups, and the polymer is then reacted with a carboxyl-group-containing drug or ligand. Conjugation efficiency is analyzed by NMR, MALDI-TOF, or size-exclusion chromatography.
|
| Cell Assay |
For cellular assays, cells are treated with drug-loaded PEG-bis-amine micelles or nanoparticles (1-100 microg/mL) for 2-72 hours. Cellular uptake is assessed by fluorescently labeled particles (flow cytometry, confocal microscopy). Cytotoxicity is measured by MTT or CCK-8. Folate-targeted micelles show enhanced uptake in folate receptor-positive cancer cells compared to non-targeted controls.
|
| Animal Protocol |
PEG-bis-amine-based nanoparticles or micelles (e.g., folate-conjugated 9-nitrocamptothecin-loaded micelles) are administered intravenously (tail vein injection) to tumor-bearing mice (typically 5-20 mg/kg polymer equivalent). Tumor volume is measured over time to assess antitumor efficacy. Biodistribution studies quantify drug accumulation in tumors versus healthy organs. Body weight and survival are monitored for safety assessment.
|
| ADME/Pharmacokinetics |
PEG-bis-amine has no intrinsic pharmacokinetics as it is a polymer vehicle. When conjugated to a drug, the conjugate's PK is determined by the molecular weight and surface chemistry. PEGylation (attachment of PEG) generally increases circulation half-life, reduces renal clearance, and decreases immunogenicity of the conjugated therapeutic agent. PK can be tailored by varying PEG MW and conjugation chemistry.
|
| Toxicity/Toxicokinetics |
PEG polymers, including PEG-bis-amine, are generally recognized as safe (GRAS) by the FDA for use in pharmaceuticals, medical devices, and cosmetics. At typical doses used in drug delivery formulations (10-100 mg/kg in animals), PEG-bis-amine is nontoxic. High doses may cause vacuolation in certain tissues but are generally reversible. PEG-related hypersensitivity is rare.
|
| References | |
| Additional Infomation |
PEG-bis-amine (MW 8000) (CAS: 24991-53-5) is a research-grade polymer used for bioconjugation and drug delivery. It is available with various PEG chain lengths (MW 2000, 5000, 8000, 10000, 20000). It should be stored at 4degC, protected from light. It is not an approved drug itself, but PEG is widely used in FDA-approved PEGylated drugs and devices. The polymer is for research use only.
|
| Molecular Formula |
(C2H4O)NC4H12N2O
|
|---|---|
| Molecular Weight |
8000(Average)
|
| Exact Mass |
148.121
|
| CAS # |
24991-53-5
|
| Appearance |
White to off-white solid powder
|
| Density |
1.003g/cm3
|
| Boiling Point |
241ºC at 760mmHg
|
| Flash Point |
>110℃
|
| LogP |
0.337
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
